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Abstract
Background/Methods: At a consensus meeting in August 2018, pediatricians and 
dermatologists from German-speaking countries discussed the therapeutic strategy for the 
treatment of pediatric patients with types I and II hereditary angioedema due to C1 inhibitor 
deficiency (HAE-C1-INH) for Germany, Austria, and Switzerland, taking into account the current 
marketing approval status. HAE-C1-INH is a rare disease that usually presents during childhood 
or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as 
early as possible and an optimal management of the disease are important to avoid ineffective 
therapies and to properly treat swelling attacks. This article provides recommendations for 
developing appropriate treatment strategies in the management of HAE-C1-INH in pediatric 
patients in German-speaking countries. An overview of available drugs in this age group is 
provided, together with their approval status, and study results obtained in adults and pediatric 
patients.
Results/Conclusion: Currently, plasma-derived C1 inhibitor concentrates have the broadest 
approval status and are considered the best available option for on-demand treatment of 
HAE-C1-INH attacks and for short- and long-term prophylaxis across all pediatric age groups in 
German-speaking countries. For on-demand treatment of children over 2 years of age, 
bradykinin-receptor icatibant is an alternative. For long-term prophylaxis in adolescents, the 
parenteral kallikrein inhibitor lanadelumab has recently been approved and can be recommended 
due to proven efficacy and safety.
Keywords: C1-INH (C1 inhibitor), hereditary angioedema, consensus, treatment, pediatric.
Abbreviations:
BK bradykinin
C1-INH C1 inhibitor (C1-esterase inhibitor)
CHMP Committee for Medicinal Products for Human Use
EAACI European Academy of Allergy and Clinical Immunology
FXII(a) Factor XII (activated)
HAE hereditary angioedema
HAE-C1-INH hereditary angioedema due to C1 inhibitor deficiency
IU international unit
pdC1-INH plasma-derived C1 inhibitor concentrate
rhC1-INH recombinant C1 inhibitor concentrate
SERPING1 serine protease inhibitor, clade G, member 1
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Introduction
Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency (HAE-C1-INH) is a rare 
disease that usually first manifests itself during childhood or adolescence as recurrent 
spontaneous swellings of the skin and mucosal tissues, resulting in skin disfigurement, colicky 
abdominal pain, or obstruction of the upper airways. There is no cure for HAE-C1-INH but 
effective treatments are on the market to manage the symptoms. Current guidelines for treatment 
and management include an international guideline with the focus in adult patients and only two 
recommendations specifically for children not taking into account the regulatory status of products 
and clinical praxis in specific countries1, an international consensus on the diagnosis and 
management of pediatric patients,2 and a guideline aimed at physicians treating patients with 
HAE-C1-INH in Germany.3
Our first consensus specifically tailored to pediatric patients in German-speaking countries was 
issued in 2012.4 At a consensus meeting, experts from Germany, Austria, and Switzerland 
formulated recommendations for developing appropriate treatment strategies. To update these 
recommendations, taking into account changes in marketing approval, recent research, and new 
therapeutic options, another meeting was held in August 2018.
The resulting consensus intends to provide physicians in German-speaking countries with a 
guideline to achieve optimal management of HAE-C1-INH in pediatric patients. The 
recommendations provided cannot be the sole basis for a treatment decision, but the individual 
course of disease, life circumstances, and wishes of the patients must be considered.
These recommendations correspond to the high standard of drug availability in German-speaking 
countries. As it would be desirable to have these conditions also in countries outside Central 
Europe, an additional aim is to promote medical awareness across countries by publishing this 
consensus.
Pathophysiology of hereditary angioedema
The various known forms of HAE have a bradykinin (BK)-mediated pathophysiology. In the 
majority of cases, patients have either insufficient levels of C1-INH protein (type I) or normal or 
elevated levels along with reduced function (type II). Both forms result from mutations in the gene 
encoding C1-INH (SERPING1). C1-INH is the main inhibitor of the active contact system 
proteases, plasma kallikrein and coagulation factor XII (FXII). Deficiency of C1-INH therefore 
leads to dysregulation of the contact and kinin systems, resulting in overproduction of BK that 
causes an increase in vascular permeability and thus promotes angioedema formation.5 In 75% 
to 80% of patients, HAE-C1-INH is inherited as an autosomal dominant trait1 and occurs de novo 
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HAE forms other than HAE-C1-INH involve edema formation in patients with normal C1-INH. 
They are caused by mutations in other genes, such as F12, resulting in enhanced activation of 
FXII, or the genes for plasminogen and angiopoetin-1.5 Recently, a mutation in the gene 
encoding kininogen 1 that changes the N-terminal cleavage site of BK has been associated with 
HAE.6 These other forms only rarely affect children,7 which is why HAE with normal C1-INH 
(formerly named HAE type III) is not further discussed here.
The network for genetic control of BK metabolism is just evolving and genetic studies may 
elucidate unknown aspects of angioedema pathogenesis and heterogeneity5 by identifying further 
genes potentially involved in the regulation of BK production, its cleavage, and edema formation.8
Recommendations for diagnosis
How to recognize HAE-C1-INH
In the majority of patients, first symptoms of HAE-C1-INH occur during childhood or early 
adolescence,2 often as recurrent abdominal pain caused by swelling of the intestinal wall.9 Being 
only rarely seen in other types of angioedema, this may be a distinguishing feature. Other 
common symptoms include swelling of the extremities, face, thoracic wall and genital region, and 
life-threatening edemas in the upper airways.
Delays of several years until a diagnosis is established, during which patients suffer from wrong 
diagnoses, treatments, and unnecessary surgical interventions, are not uncommon.10,11 This is 
partly because the disease is rare and not well known among physicians, but also because 
symptoms are ambiguous and resemble those of other diseases. Particularly abdominal attacks 
are sometimes accompanied by vomiting and diarrhea, both frequent symptoms in childhood. In 
cases of recurrent, unclear abdominal pain, we therefore strongly recommend sonography during 
an acute phase, whereby a thickening of the bowel wall in particular is a sign of HAE-C1-INH.12 
However, mild intestinal edema may be overlooked on imaging even in symptomatic patients13 so 
that negative scans do not necessarily exclude a diagnosis of HAE-C1-INH.
External swelling sites are pale, hard, and doughy, sometimes causing considerable tension-
induced pain. They mimic mast cell-mediated angioedema, but are not accompanied by pruritic 
wheals. Accordingly, HAE-C1-INH is unlikely with recurrent itching urticarial wheals, whereas 
erythema marginatum, a non-itching sharply defined rash, is a prodromal symptom that has also 
been reported in very young children.14,15
Triggers of an attack cannot always be determined. However, known potential triggering factors 
such as emotional distress, physical trauma, infection, changes in estrogen levels, and certain 
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Testing procedure
For an accurate diagnosis of types I or II HAE-C1-INH, determination of C1-INH antigen 
concentration and function (with a chromogenic substrate assay) in plasma are usually sufficient. 
Genetic testing for SERPING1 mutations is not indicated for routine diagnosis and should only be 
done in special cases when all other values are within the normal ranges.
As most patients have persistently low antigen C4 levels,3 C4 testing, having a high level of 
specificity and sensitivity for HAE-C1-INH,19 can provide clarity in cases with unclear findings.3 C4 
testing alone with unknown C1-INH concentration and function is not sufficient for diagnosis, 
because normal C4 levels do not necessarily exclude HAE-C1-INH and low C4 levels may be 
caused by other conditions.20,21
Because C1-INH is an acute phase protein, blood sampling for laboratory diagnostics should 
primarily be performed during attack-free periods and in the absence of inflammatory processes.
Diagnostics should always be done in accredited laboratories using validated assays. 
Commercially available tests with positive, negative, and calibration samples are recommended.
Interpretation of results should take into account age-dependent normal values. Especially before 
the age of 1 year, antigenic and functional C1-INH levels are often lower than in adults.2
Time of diagnosis
All patients with suspected HAE-C1-INH, whether due to conspicuous symptoms or a known 
family history, should be tested. Because of the considerable consequences of a diagnosis, a 
positive test should be repeated and confirmed.
Newborns with a positive family history are considered potentially affected until HAE-C1-INH is 
excluded and must be well observed and tested as early as possible, to ensure optimal 
management of the disease. This is particularly important in view of the potentially fatal outcome 
of upper airway attacks.1 A valid diagnosis based on C1-INH activity, C1-INH antigen 
concentration, and C4 testing can be performed from the age of 4 weeks on and is to be verified 
at the age of 1 year. It is important that physicians mention, if necessary repeatedly, that other 
family members ought to be tested for their disease status.2
Prenatal testing is not recommended because a diagnosis at this time has no direct 
consequences for mother or child and there are no known cases of in utero symptoms.2 Likewise, 
testing umbilical cord blood is not recommended as even in unaffected children, antigenic and 
functional C1-INH cord blood levels are only approximately 70% and 62% of adult normal 
values.2
Therapeutic options and clinical evidence
HAE-C1-INH therapeutics are described below, their approval status summarized in Table 1, and 
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Data from studies in pregnant and nursing mothers are not considered.
Human plasma-derived C1-INH concentrates
Human plasma-derived C1-INH (pdC1-INH) concentrates replace and take over the function of 
the missing or nonfunctional protein in inhibiting contact activation and the kallikrein-kinin system 
(Figure 1). Currently, two pdC1-INH products, Berinert® (CSL Behring GmbH, Marburg, Germany) 
and Cinryze® (Shire Services BVBA, Bruxelles, Belgium [part of Takeda Pharmaceutical 
Company Limited]) are available for pediatric patients (Table 1). See Table 2 for specific risks.
pd C1-INH (Berinert)
pdC1-INH (Berinert) is available as a 500 international unit (IU) application set for intravenous 
injection, and a reduced-volume formulation (1500 IU vial) enabling shorter treatment time.22 It is 
also available as sets of 2000 or 3000 IU for subcutaneous application.
See Table 1 for the approval status.
On-demand treatment with intravenous pdC1-INH (Berinert):
Efficacy and safety of 20 IU/kg pdC1-INH (Berinert) have been shown in the pivotal randomized, 
double-blind, placebo-controlled study I.M.P.A.C.T.1 in 124 patients, including pediatric 
patients,23 and were confirmed for long-term therapy in the open-label extension I.M.P.A.C.T.2 in 
57 patients, also including pediatric patients.24
For 20 pediatric patients, efficacy and safety were confirmed in a retrospective observational 
study on on-demand home therapy, which concluded that, as in adults, home therapy with pC1- 
INH is effective and safe in the treatment of HAE-C1-INH attacks in pediatric patients.25
See Table 3 for a short summary of studies.
 Short-term prophylaxis with intravenous pdC1-INH (Berinert):
No specific results are available for short-term prophylaxis in children and adolescents but 
efficacy and safety were confirmed in a patient survey of 171 patients26 and the Berinert registry27 
of 79 patients, which also included pediatric patients. See Table 3 for a short summary.
Long-term prophylaxis with subcutaneous pdC1-INH (Berinert):
Efficacy and safety of twice weekly 40 or 60 IU/kg subcutaneous pdC1-INH (Berinert) 
(HAEGARDA® in the United States) were shown in the randomized, double-blind COMPACT 
study for 90 patients. No specific results have been reported for pediatric patients, the study 
included patients from the age of 17 years.
Similarly, the randomized, open-label extension of COMPACT, including pediatric patients from 
the age of 8 years, demonstrated that long-term replacement therapy with subcutaneous pdC1-
INH (Berinert) is safe with a substantial and sustained prophylactic effect.29
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A subgroup analysis of COMPACT showed that switching from intravenous to subcutaneous 
long-term prophylaxis may result in a significant benefit for patients.30 Additional clinical 
experience and further studies are needed to confirm these observations.
Additional safety information for pdC1-INH (Berinert):
For intravenous pdC1-INH (Berinert), the product information leaflets state that there are no very 
common, common, or uncommon adverse reactions from postmarketing experience and scientific 
literature.
For subcutaneous pdC1-INH (Berinert), nasopharyngitis (runny or stuffy nose, sneezing, watery 
eyes) and injection site reactions are listed as very common, hypersensitivity (itching and rash) 
and dizziness are common.
pdC1-INH (Cinryze)
The other approved pdC1-INH, pdC1-INH (Cinryze), is available as a 500 IU application set for 
intravenous injection.
See Table 1 for the approval status.
On-demand treatment with pdC1-INH (Cinryze):
A randomized, double-blind, placebo-controlled study showed good efficacy and safety for 
on-demand 1000 IU pdC1-INH (Cinryze) in 68 adult patients, including 12 children from the age 
of 6 years.31 This benefit was confirmed for repeated treatment in an open-label extension in 
113 patients, including 22 children from the age of 2.32
In an open-label study in 9 children <12 years, on-demand treatment with either 500 IU, 1000 IU, 
or 1500 IU pdC1-INH (Cinryze) was safe and effective.33 It was therefore concluded that doses of 
<1000 IU may be appropriate in some pediatric patients.
See Table 3 for a short summary of studies. 
Long-term prophylaxis with pdC1-INH (Cinryze):
Of the patients in the acute-treatment study described above, 22 were treated in a long-term 
prophylaxis study, which included 4 patients ≤18 years of age and confirmed efficacy of pdC1-
INH.31
The open-label extension in 146 patients, included 23 children from the age of 3.34 The study 
showed that at 1000 IU twice weekly, pdC1-INH (Cinryze) was highly effective and safe in the 
majority of patients.
Likewise, in 12 children, routine prophylaxis was efficacious and safe in a randomized, 
single-blind Phase III study.35 
See Table 4 for a short summary of studies.
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In the current E.U. Summary of Product Characteristics [SmPC] and Swiss product information, 
headache and nausea are listed as very common (in ≥1/10 cases), indicated by data from clinical 
studies and postmarketing reports. Hypersensitivity, dizziness, vomiting, rash, erythema, pruritus, 
injection site reactions, and pyrexia are common (≥1/100 to <1/10).
Recombinant human C1-INH concentrate
The active ingredient of recombinant human C1-INH concentrate (rhC1-INH) (Ruconest®, 
Pharming Group NV, Leiden, the Netherlands), conestat alfa, is a recombinant analog of 
pdC1-INH, produced in transgenic rabbits and purified from their milk. Its glycosylation is not 
identical to that of human C1-INH, which is presumably the reason for its shorter half-life of 
approximately 2 hours (current E.U. SmPC) but its function is the same (Figure 1). 
rhC1-INH is available as a 2100 IU application set for intravenous injection.
See Table 1 for the approval status.
On-demand treatment with rhC1-INH:
Two randomized, double-blind, placebo-controlled studies were conducted in 70 patients (from 17 
years on), that showed good efficacy and safety for 50 IU/kg rhC1-INH.36 
For 20 pediatric patients, the favorable results were confirmed in an open-label, single-arm 
Phase II study.37
So far, no head-to-head comparison with pdC1-INH concentrates has been published.
See Table 3 for a short summary of studies.
Additional safety information for rhC1-INH:
The most common (in ≥1/100 to <1/10 cases) adverse reaction across clinical studies was 
headache (current E.U. SmPC). Other adverse reactions, mostly mild or moderate, occurred in 
<1/100 patients. Efficacy and safety in adolescent patients were consistent with those seen in 
adults. See Table 2 for specific risks.
Bradykinin-receptor antagonist icatibant
Icatibant (Firazyr®, Shire Orphan Therapies GmbH, Berlin [part of Takeda Pharmaceutical 
Company Limited]) is a chemically synthesized decapeptide with a BK-like structure rendering the 
molecule resistant to enzymatic degradation. It is a selective antagonist of the BK B2 receptor 
that inhibits the interaction of BK with endothelial cells (Figure 1). 
Icatibant is available as a 30 mg solution for subcutaneous injection in a pre-filled syringe.
See Table 1 for the approval status.
On-demand treatment with icatibant:
In adult patients, the FAST study program, including 3 randomized double-blind studies, showed 
superiority of icatibant: in FAST-1 versus placebo for 56 patients38 followed by an open-label 
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label extension period40, and in FAST-3 versus placebo for 88 patients, with efficacy and safety 
being confirmed for multiple attacks during an open-label extension period.42 
For 11 children and 11 adolescents, a non-randomized, open-label Phase III study, confirmed 
efficacy of a single dose of icatibant (0.4 mg/kg; maximum 30 mg).43
During FAST-1 and FAST-2, there was evidence that a single dose of icatibant was not sufficient 
in some patients. This observation is supported by real-life data from the Icatibant Outcome 
Survey, which reports that 81% of 652 attacks resolved with a single injection of icatibant, 
compared with 19% that required one or more additional injections of icatibant and/or C1-INH 
rescue medication.44
See Table 3 for more details on the studies.
Additional safety information for icatibant:
Across clinical studies, for adult patients, the current E.U. SmPC and Swiss product information 
list injection site reactions as very common (in ≥1/10 cases) and the following adverse reactions 
as common (≥1/100 to <1/10): dizziness, headache, nausea, rash, erythema pruritus, pyrexia, 
and increased transaminases. See Table 2 for specific risks.
Kallikrein inhibitors
Lanadelumab
Parenteral kallikrein inhibitor lanadelumab (Takhzyro®, Shire Pharmaceuticals Ireland Limited 
[part of Takeda Pharmaceutical Company Limited]), with its active substance lanadelumab, is a 
monoclonal antibody inhibiting the increased plasma kallikrein proteolytic activity that leads to 
angioedema attacks through proteolysis of high-molecular-weight kininogen to generate BK 
(Figure 1). Lanadelumab is available as a 300 mg solution for subcutaneous injection. See Table 1 
for the approval status.
Long-term prophylaxis with lanadelumab:
Efficacy and safety of long-term prophylaxis with different doses of lanadelumab were shown in 
the randomized, double-blind, placebo-controlled HELP study in 125 patients, including 
10 adolescents ≥12 years of age.45 Results for adolescents are not explicitly reported.
Additional safety information for lanadelumab:
In the current E.U. SmPC the following adverse events are listed as being very common (≥1/10): 
injection site reactions; and common (≥1/100 to <1/10): hypersensitivity, dizziness, maculo-
papular rash, myalgia, and increased alanine and aspartate aminotransferases.
Safety of lanadelumab in a subgroup of 23 patients between 12 and <18 years was consistent 
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Ecallantide
The active substance in Kalbitor® (Dyax Corp., Cambridge, MA, USA) is ecallantide (DX-88), a 
60-amino-acid recombinant protein, which blocks kallikrein and is thereby expected to help 
reduce swelling attacks (Figure 1). Impaired control of kallikrein activity results in increased 
circulating BK levels, leading to increased endothelial permeability and leaking of fluid into the 
tissue, which in turn causes swelling.
During the submission process to receive marketing authorization from the European Medicines 
Agency, Dyax S.A. withdrew its application. Based on review of the submitted data and the 
company’s response to the Committee for Medicinal Products for Human Use (CHMP) list of 
questions, the CHMP had concerns about hypersensitivity reactions, which were seen at a higher 
rate in patients treated with ecallantide, and about effectiveness of the proposed doses in heavier 
patients. Therefore, the CHMP concluded that the benefits of ecallantide did not outweigh its 
risks. Ecallantide is thus not approved in the European Union or any of the German-speaking 
countries (Table 1). In the United States, ecallantide has a boxed warning, highlighting the risk of 
anaphylaxis, see Table 2.
Attenuated androgens
In many parts of the world, attenuated androgens are used for short- and long-term prophylaxis in 
HAE-C1-INH, causing an increase in C1-INH plasma levels. They are not approved anymore in 
German-speaking countries (Table 1) and guidelines explicitly do not recommend androgens for 
long-term prophylaxis in young children.1,2 For short-term prophylaxis, attenuated androgens 
(e.g., danazol) have been recommended in the past, even in children. Recent guidelines, 
however, recommend pdC1-INH concentrate as prophylaxis of choice.1
Because androgens may interfere with the natural growth, bone maturation, and sexual 
development of children46 and have numerous other side effects, see Table 2, we consider their 
use contraindicated in pediatric patients and do not recommend this option. No appropriate 
clinical studies have been performed in children and adolescents with HAE-C1-INH and only a 
small case series provides some data on the efficacy and tolerability at low doses.47
Antifibrinolytics
Antifibrinolytics (ε-aminocaproic acid or tranexamic acid [cyclic analog of ε-aminocaproic acid]), 
such as Cyklokapron® (Meda Pharma, Bad Homburg, Germany), are chemically synthesized and 
exert their action in HAE-C1-INH by inhibiting the conversion of plasminogen to plasmin, and 
thereby activation of FXII (Figure 1). Antifibrinolytics are available as tablets for oral application. 
See Table 1 for the approval status.
Antifibrinolytics are used to treat HAE-C1-INH in many parts of the world for lack of better 
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profile, see Table 2, they are sometimes propagated as a possible option for prophylaxis in 
children.48 Two early double-blind, placebo-controlled studies (in 5 and 18 patients) showed a 
reduction in attack frequency.49,50 A more recent prospective study comparing long-term 
prophylaxis in patients with and without tranexamic acid did not demonstrate any effect.51 As 
more effective options are available, we do not recommend tranexamic acid for pediatric patients 
despite an existing approval. 
Experimental approaches
A variety of experimental approaches have been discussed for HAE-C1-INH management, none 
of which can be recommended from today's perspective. These include antisense-mediated 
inhibition of either activated FXII or prekallikrein, which alleviated the effects of C1-INH depletion 
in a mouse model.52
A case of severe HAE in a previously HAE-negative subject after having received a liver 
transplant from a HAE-positive donor has been reported. Conversely, it is discussed whether 
HAE could be cured by transplanting a healthy liver.53 To date, no such case is known.
Somatic gene therapy using an adenoviral vector carrying wildtype SERPING1 gene provided 
sustained increase of human C1-INH activity levels in a mouse model and could potentially 
provide long-term protection from HAE-C1-INH attacks.54 No data are yet available in humans.
General recommendations
All of the approved drugs are generally effective. In case of several possible treatment options, 
the choice should be discussed and advantages and disadvantages of therapies weighed up. The 
current drug approvals in the individual countries must be taken into account before deciding on 
an off-label treatment in carefully selected cases.
The following general recommendations are intended to provide guidance and simplify disease 
management. The individual clinical picture, external circumstances, and patient wishes must 
also be taken into account when establishing a therapy.
Patient care
Cooperation with a dedicated HAE center is essential to provide patients with access to disease-
specific comprehensive care.
An action plan shows the patient and parents how to act in certain situations for optimal disease 
management at home and at daycare/school. This includes learning how to recognize prodromal 
signs and being sensitized to possible triggers.
An emergency medical card with the diagnosis and recommended treatment may prevent 
treatment delay and wrong medication.
The patient should keep a diary where each swelling is documented together with the medication 
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In general, a weight-dependent dosage is desirable for children and adolescents.
Self-administration
Home self-treatment under medical supervision is feasible for many patients, including children 
and adolescents. Patients, parents, and caregivers must be sufficiently trained in self-
administration techniques and made aware of special precautions with respect to storage and 
handling.
Hormones for contraception
It is well known that sexual hormone fluctuations can influence attack frequency, and 
menstruation has long been recognized as a trigger in some women.2 Puberty has also been 
reported to exacerbate the disease, as have been estrogen-containing contraceptives which 
should therefore be avoided.55 Progestin-containing contraceptives may alleviate HAE-C1-INH 
symptoms, which is why, if well tolerated, these can be taken from the time of menarche.
Recommendations for on-demand therapy
With regard to the safety of the child, there is agreement that in very young patients under the 
age of 6, every attack should be treated. The recommended medications are safe and the 
benefits of treatment outweigh the risks. If there is no symptom relief upon self-treatment, an 
experienced physician must be consulted immediately.
In general, this also applies to children over 6 years. However, it is acceptable in certain 
situations with mild peripheral and gastrointestinal attacks without any progression or interference 
with everyday activities, to follow a wait-and-see approach.
It is strongly recommended to always treat attacks affecting the neck and head area, in particular 
if the upper respiratory tract is involved. Hospital admission may be necessary. Treatment of an 
attack in this area should start as soon as possible to stop further edema formation and promote 
its rapid regression.56
Recurrent abdominal attacks or attacks for which an otherwise effective treatment remains 
ineffective should be confirmed sonographically to rule out other possible causes.
Emergency HAE-specific medicine for the treatment of at least two attacks must be available to 
patients and within easy reach at all times.
In general, pdC1-INH concentrates and icatibant are recommended for on-demand treatment in 
children (Table 4). For dosing see Table 1. Icatibant is injected subcutaneously, and is a stable 
ready-to-use product with no need for reconstitution that can be easily taken along. Sustainability 
of the treatment effect is somewhat lower than of pdC1-INH. According to the current E.U. SmPC 
and Swiss product information, in case of insufficient relief or symptom recurrence, adults can 
administer a second injection after 6 hours and a third after a further 6 hours. For children, no 
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most cases they require only one application, and the disadvantage of intravenous administration 
(for on-demand treatment).
As no head-to-head comparative studies are available for pdC1-INH and icatibant, priority for one 
of the products cannot be determined but has to be agreed upon between physician and patient; 
a treatment decision must be based on individual factors such as product availability, patient’s 
tolerance and possibility for easy venous access, adverse effects, and need for re-dosing with a 
product.
Recommendations for short-term prophylaxis
There are reports on patients who died of laryngeal attacks after dental treatment.26 Therefore, 
short-term prophylaxis is recommended before procedures such as dental treatment with 
significant traumatization of the gums (with and without intubation), procedures requiring 
endotracheal intubation, surgical interventions in the neck and head area, and other essential 
surgical procedures. Even with short-term prophylaxis, emergency medication (pdC1-INH or 
icatibant) must be available for immediate use in case of breakthrough attacks.
Short-term prophylaxis is also recommended for stressful life events that may trigger an attack.
In cases where it is unclear whether short-term prophylaxis should be given, the attending 
physician should contact the HAE center to achieve a decision.
We recommend to administer short-term prophylaxis as close as possible (30 minutes to 1 hour) 
to the planned procedure to ensure high plasma levels.
Only intravenous pdC1-INH concentrates are recommended for short-term prophylaxis in 
pediatric patients (Table 4). For dosing see Table 1. Previous recommendations of androgens and 
tranexamic acid are outdated due to the reasons described above. 
Recommendations for long-term prophylaxis
The decision whether long-term prophylaxis is indicated must primarily be made by the physician. 
If the medical prerequisites are met, the patient should be involved in the decision process as to 
whether and how prophylaxis is to be established. Dosage and treatment interval should be 
adjusted so that the patient's individual burden of disease is minimized and costs are reasonable.
We do not recommend long-term prophylaxis in patients with less than two attacks per month. 
Potential candidates are those with more frequent attacks, high disease burden, and severe 
impairment of everyday life, who cannot sufficiently control their HAE-C1-INH with on-demand 
therapy.
Attenuated androgens cannot be recommended for long-term prophylaxis in children due to the 
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Long-term prophylaxis cannot be recommended in patients younger than 2 years of age. For 
children younger than 6 years, there is no sufficient evidence available and no medication is 
approved. Options for older children and adolescents include pdC1-INH concentrates and 
lanadelumab, see Table 4 and Table 1 for dosing.
As no head-to-head comparative studies are available for pdC1-INH and lanadelumab, priority for 
one of the products cannot be set. For a treatment decision, factors such as product availability, 
patient’s tolerance and possibility for easy venous access, and treatment frequency must be 
taken into account. A decision on which drug to use should be made between physician and 
patient after weighing up all advantages and disadvantages.
Future perspectives
Oral kallikrein inhibitors
A potent small molecule inhibitor of plasma kallikrein, BCX7353, significantly lowered the attack 
rate compared with placebo when administered once daily at doses of at least 125 mg.57 
On-demand treatment with 750 mg of the same compound had superior efficacy compared with 
placebo and was safe in a double-blind, placebo-controlled, randomized, crossover study in 
adults with HAE-C1-INH.58
A third potent selective small molecule plasma kallikrein inhibitor, KVD900, with pharmacokinetic 
properties well suited for rapidly-acting treatment of attacks, is currently being tested in a 
randomized, double-blind, placebo-controlled, Phase II, crossover study.59
Oral drugs for treatment of attacks in HAE-C1-INH patients, especially children, are highly 
desirable. We look forward to publication of appropriate clinical studies.
Factor XII antibodies
A humanized anti-FXIIa monoclonal antibody is in development for use in multiple indications 
including subcutaneous HAE-C1-INH therapy.60,61 A randomized, placebo-controlled, 
parallel-arm, Phase II study is currently ongoing to investigate the clinical efficacy, 
pharmacokinetics, and safety of CSL312 prophylaxis to prevent attacks in adult patients.
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Tables
Table 1: Approval status and dosing of products for the treatment of HAE-C1-INH in German-speaking countries (as of September 2019)
Dosing per age groupProducts
(application mode) Countries
Home 
therapy On demand Short-term prophylaxis Long-term prophylaxis
pdC1-INH
Germany + Austriab possible ≥0 y: 20 IU/kg 0-<18 y: 15-30 IU/kg
≥18 y: 1000 IU
—Berinert® 500/1500a 
(i.v.)
Switzerland possible ≥0 y: 20 IU/kg ≥0 y: 20 IU/kg —
Germany + Austria possible — — ≥12 y: 60 IU/kg 2x/week Berinert® 2000/3000 
(s.c.) Switzerland — — — —
Cinryze® (i.v.) E.U. possible 2-11 y (10-25 kg): 500 IU
≥2 y (>25 kg): 1000 IU
2-11 y (10-25 kg): 500 IU
≥2 y (>25 kg): 1000 IU
6-11 y: 500 IU every 3-4 days
≥12 y: 1000 IU every 3-4 days
Switzerland possible ≥6 y: 1000 IU ≥6 y: 1000 IU ≥6 y: 1000 IU every 3-4 days
rhC1-INH
Ruconest® (i.v.) E.U. possible ≥12 y:
<84 kg: 50 IU/kg
≥84 kg: 4200 IU
— —
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Firazyr® (s.c.) E.U. + Switzerland possible 2 -<18 y:
12-25 kg: 10 mg
26-40 kg: 15 mg
41-50 kg: 20 mg
51-65 kg: 25 mg
>65 kg: 30 mg
≥18 y: 30 mg
— —
Lanadelumab
Takhzyro® (s.c.) E.U. + Switzerland possible — — ≥12 y: 300 mg/2 weeksc
Tranexamic acid 
Cyklokapron® (oral) Germany possible — up to 3x1.5 g up to 50 mg/kg dailyd
Austria possible — 2-3x500 mg 2-3x/daye 2-3x500 mg 2-3x/daye
Switzerland possible — 25 mg/kg dailye 25 mg/kg dailye
HAE-C1-INH=hereditary angioedema due to C1 inhibitor deficiency; IU=international unit; i.v.=intravenous; pdC1-INH=plasma-derived C1 inhibitor concentrate; 
rhC1-INH=recombinant human C1 inhibitor concentrate; s.c.=subcutaneous; SmPC=Summary of Product Characteristics; y=years.
Note: Authorities responsible for approval are: in Germany the Paul Ehrlich Institut (PEI), in Austria the Bundesamt für Sicherheit im Gesundheitswesen (BASG), in 
Switzerland Swissmedic, and for central approval across the E.U. the European Medicines Agency (EMA).
a. In Switzerland, only 500 IU are approved.
b. Approved in Austria but not marketed so far.
c. May be reduced to every 4 weeks if attack free for a long period, especially for low body weight patients.










e. No age restriction according to product information.
Sources: Berinert Austrian, German, and Swiss product information; Cinryze E.U. SmPC, Swiss product information; Firazyr E.U. SmPC, Swiss product 
information; Ruconest E.U. SmPC; Takhzyro E.U. SmPC, Swiss product information.
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Risks and adverse events
Human plasma-derived C1 inhibitor concentrates
Berinert®, Cinryze® The theoretical risk of pathogen transmission associated with all plasma products is 
minimized during manufacturing by dedicated virus reduction steps. No such 
transmissions have thus far been described for these products. In this respect, 
Berinert and Cinryze can be judged to be safe. For patients who regularly take 
preparations from human blood or plasma, a vaccination against hepatitis A and B is 
generally recommended.
Recombinant human C1 inhibitor concentrate
Ruconest® A potential risk of allergic reactions and formation of neutralizing antibodies is 
associated with recombinant products. Therefore, Ruconest is contraindicated in 
patients with rabbit allergy. Hypersensitivity reactions cannot be excluded. Patients 
must be closely monitored and carefully observed for any symptoms of 
hypersensitivity throughout the administration period. The risk is considered to be 
very low. To the best of our knowledge and based on published data, this has been 
sufficiently studied and is not a practical problem.
Bradykinin-receptor antagonist
Icatibant / Firazyr® From the theoretical perspective, caution is advised in patients with ischemic heart 
disease, unstable angina pectoris, and in the first weeks following a stroke. Clinically 
relevant problems in this regard have not been observed to date, especially not in 
children. Injection site reactions (skin irritation, swelling, pain, itchiness, erythema, 




Mild hypersensitivity reactions have been observed.
Ecallantide / Kalbitor®
(not licensed outside 
Worth mentioning is the risk of anaphylactic reactions (frequency according to the 
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(not licensed outside 
U.S.)
Adverse events are numerous and include weight gain, acne, edema, hair loss, voice 
change, menstrual disturbances, amenorrhea, flushing, sweating, emotional lability, 
and hepatic dysfunction in the case of long-term treatment. In children, adverse 




The most common adverse effects are dose-dependent gastrointestinal symptoms 
(nausea, vomiting, diarrhea). There is a hypothetical risk of arterial or venous 
thromboses. The frequency of these is not known.
HAE-C1-INH=hereditary angioedema due to C1 inhibitor deficiency, smPC=Summary of Product 
Characteristics.
Note: In general, product availability depends on the capacities of validated production facilities approved 
by (local) authorities. Furthermore, plasma products are dependent on the availability of donated blood.
Sources: Berinert Austrian, German, and Swiss product information; Cinryze E.U. SmPC, Swiss product 
information; Cyklokapron Austrian, German, and Swiss product information; Danocrine U.S. package insert; 
Firazyr E.U. SmPC, Swiss product information; Frank et al. 2016; Kalbitor U.S. prescribing information; 
Ruconest E.U. SmPC; Takhzyro E.U. SmPC, Swiss product informationTakhzyro.





Dosing Short summary of key efficacy 
results
















With pdC1-INH, shorter median time 
to onset of relief (0.5 vs. 1.5 h; 
p=0.0025), secondary outcomes 
supported efficacy; pediatric 
patients: median time to onset of 
relief: 0.42 h, to complete 
resolution: 8.08 h
4 h after treatment:
no SAEs, AEs leading 









20 IU/kg i.v. Single dose sufficient in 99% of 
1085 attacks at any body location; 
pediatric patients: median time to 
onset of symptom relief: 0.4  h, to 
complete resolution: 14.1 h
Mainly mild or 
moderate AEs, 1 
discontinuation due to 
AE, no related SAEs, 
















500 / 1000 IU i.v.
physician-based 
vs. home therapy
Median time to initial symptom 
relief: 40 min (home therapy), 
60 min (physician-based)
No AEs or 
seroconversions
Short-term prophylaxis (intravenous)
With prophylaxis, 44% reduction of 
attacks (per-patient), 42% (per-attack)
No drug-related AEsPatient survey26 171 patients 500 / 1000 IU i.v. 
vs.
no prophylaxis No details reported for pediatric patients
Cumulative attack rates (CI) within 
days after treatment:
1 day: 0.04 (0.015-0.088)
2 days: 0.06 (0.028-0.115)
3 days: 0.11 (0.061-0.174)
4 days: 0.23 (0.158-0.319)
6 AEs in 6.3% of 








(range) per i.v. 
infusion: 
14.6 IU/kg (3.6-
33.9 IU/kg) or 
1,000 IU (500-
3,500 IU) No details reported for pediatric patients
Long-term prophylaxis (subcutaneous)
Median reduction in normalized 
number of attacks vs. placebo: 89% 
(40 IU), 95% (60 IU)
AEs were mainly mild, 
transient local site 








40 / 60 IU/kg s.c. 
twice weekly 
followed by 
placebo or vice 
versa No details reported for pediatric patients
Median annualized attack rates: 1.3 
(40 IU/kg), 1.0 (60 IU/kg); median 
rescue medication use: 0.2, 
0.0 times/year; 54% of 63 patients 
(60 IU/kg) symptom free during 
Months 1-6, 83% of 23 during 
Months 25-30
Low incidence of AEs, 
similar in both dose 
groups, 12 SAEs, 1 









40 / 60 IU/kg s.c. 
twice weekly











1000 IU i.v. 
vs.
placebo
With pdC1-INH, shorter median times 
to onset of unequivocal relief (all 
patients 2 vs. 4 h, p=0.02; pediatric 
patients 0.5 vs. 2 h) and complete 
resolution of symptoms (12 vs. 25 h, 
p=0.004)
No related SAEs, 











1000 IU i.v. 609 treated attacks in 101 patients: 
68% achieved unequivocal relief 
within 1 h, 87% in 4 h; pediatric 
patients (121 attacks): 79% within 
1 h, 89% in 4 h
Mainly mild or 
moderate TEAEs, no 
related SAEs, 
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Open-label study33 9 pediatric 
patients 
<12 years
i.v. 500 IU (10-
25 kg) / 1000 IU 
(>25 kg) / 1500 IU  
(>25 kg)
Median time (range) to unequivocal 
symptom relief: was 0.5 h (0.25-2.5)
Treatment with all 












1000 IU i.v. vs. 
placebo every 3-
4 days (crossover 
after 12 weeks)
With prophylaxis, shorter average 
normalized attack rates (6.26 vs. 
12.73); pediatric patients: lower 
mean number of attacks (7.0 vs. 
13.0)
88% of patients had 
AEs, no related SAEs, 










1000 IU i.v. every 
3-7 days
With prophylaxis, median monthly 
attack rate decreased from 3.0 to 0.19 
(p<0.001); pediatric patients: 3.0 to 
0.39
No related SAEs, 














With prophylaxis, reduced mean 
monthly normalized number of 
attacks (SD) by 71% (27%) with 





Median time to beginning of symptom 
relief faster with 50 IU/kg (122 min; 
p=0.013) and 100 IU/kg rhC1-INH 
(66 min; p<0.001) vs. placebo (495 
min)
No related SAEs, 
discontinuations due to 








50 / 100 IU/kg i.v. 
vs.
placebo






50 IU/kg i.v. Efficacious and safe, overall 
median time to beginning of 
symptom relief: 60 min





With icatibant, shorter median times to 
first symptom improvement (1.0 vs. 
5.7 h; p<0.001) and significant 
symptom relief (2.5 vs. 4.6 h; p=0.14), 
rescue therapy: 11% (icatibant) vs. 
45% (placebo) of patients
No SAEs, 









30 mg s.c. 
vs.
placebo
No pediatric patients included in the study
1 injection sufficient in 88% of 





30 mg s.c. 
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With icatibant, shorter median times to 
first symptom improvement (1.5 h vs. 
6.9 h; p<0.001) and significant 
symptom relief (2.0 h vs. 12.0 h; 
p<0.001)
No related SAEs, 









30 mg icatibant 
s.c. + placebo p.o.
vs. 3 g tranexamic 
acid p.o. + 
placebo s.c.
No pediatric patients included in the study
Median time to onset of symptom 
relief: 2.0 h, second injection for 10% 
of 374 attacks




30 mg s.c. 
No pediatric patients included in the study
With icatibant, shorter median times to 
≥50% reduction in symptom severity 
(2.0 vs. 19.8 h; p<0.001), onset of 
primary symptom relief (1.5 vs. 18.5 h; 
p<0.001), almost complete symptom 
relief (8.0 vs. 36.0 h; p=0.012), no 
need for rescue medication
No related SAEs, 









30 mg s.c. 
vs.
placebo
No pediatric patients included in the study
Similar median times to onset of 
primary symptom relief and almost 
complete symptom relief as in FAST-3







30 mg s.c. 
No pediatric patients included in the study
NCT0138665843





0.4 mg/kg s.c. ; 
max: 30 mg
Median time to onset of symptom 
relief: 1.0 h
TEAEs were mild or 
moderate, no related 
serious TEAEs
Lanadelumab Long-term prophylaxis
With lanadelumab, lower mean 
monthly attack rate (0.26-0.53 vs. 
1.97 attacks; p<0.001), higher number 
of attack-free patients (31%-44% vs. 
2%; p<0.001) and attack-free 
days/month (26.9-27.3 vs. 22.6 days; 
p<0.001), lower need of C1-INH on-
demand medication (20% vs. 66%)
Mostly mild or 
moderate TEAEs, most 
common related TEAE: 
injection site pain 












150 mg every 
4 weeks, 300 mg 
every 4 weeks, or 
300 mg s.c. every 
2 weeks,
vs. placebo for 
26 weeks
No details reported for pediatric patients
AB=antibody; AE=adverse event; CI=confidence interval; IU=international unit; i.v.=intravenous; pdC1-INH=plasma-
derived C1-INH inhibitor concentrate; p.o.=oral; rhC1-INH=recombinant C1 inhibitor concentrate; SAE=serious adverse 
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Age groups
Therapy 0-<2 y 2-<6 y 6-<12 y ≥12 y
On demand










General  Always treat attacks affecting the neck and head area
 Treat as early as possible
 Children <6 y: also treat attacks at all other body locations
 Children ≥6 y: consider attacks at all other body locations for on-demand 
treatment
 Keep emergency medicine available and within easy reach at all times
Short-term prophylaxis






General  Recommended for all medical procedures with significant tissue traumatization 
and surgical interventions in neck and head area
 For procedures where short-term prophylaxis is not given, keep emergency 
C1-INH concentrate available
 Administer as shortly as possible before the planned procedure
Long-term prophylaxis
Products  Not 
recommended
 None approved  Cinryze (i.v.)  Berinert (s.c.)
 Cinryze (i.v.)
 Takhzyro (s.c.)
General  For long-term prophylaxis treatment decision, consider frequency of attacks, 
disease burden, and impairment of everyday life
i.v.=intravenous; s.c.=subcutaneous; y=years.
Note: See Table 1 for the approved dosing for each age group.
a. In Switzerland, Cinryze is not approved for children under 6 years of age.
Figure legend
Figure 1: Pathogenesis of hereditary angioedema and possible points of action for therapeutics










Table 4: Recommendations by age groups (as of September 2019)
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Note: FXII is activated to FXIIa, e.g. by plasmin derived from plasminogen. FXIIa converts prekallikrein, 
which is in complex with HMWK, to kallikrein. Kallikrein can enhance FXII activation via positive feedback in 
addition to FXII autoactivation. Kallikrein also cleaves HMWK to cHMWK and releases BK. Reaction of BK 
with BKR2, induces increased endothelial permeability, resulting in the formation of tissue edema. Possible 
points of action for approved drugs are indicated by a "STOP" sign. 
The degradation of BK is not shown here: BK is either inactivated by angiotensin converting enzyme (ACE) 
or is transformed by carboxypeptidase N to its des-Arg-metabolite, which can react with BKR1 and, to a 
much lesser extent, with BKR2, thereby also inducing vasodilation and edema formation.
Modified from Busse P and Christiansen C;N Engl J Med 2020;382(12):1136-1148 and Cicardi M, Zuraw 










Figure 1: Pathogenesis of hereditary angioedema and possible points of action for therapeutics 
 
 
BK=bradykinin; BKR2=bradykinin receptor 2; C1-INH=C1 inhibitor; FXII(a)=(activated) Factor XII; 
(c)HMWK=(cleaved) high-molecular-weight kininogen. 
Note: FXII is activated to FXIIa, e.g. by plasmin derived from plasminogen. FXIIa converts prekallikrein, 
which is in complex with HMWK, to kallikrein. Kallikrein can enhance FXII activation via positive feedback 
in addition to FXII autoactivation. Kallikrein also cleaves HMWK to cHMWK and releases BK. Reaction of 
BK with BKR2, induces increased endothelial permeability, resulting in the formation of tissue edema. 
Possible points of action for approved drugs are indicated by a "STOP" sign.  
The degradation of BK is not shown here: BK is either inactivated by angiotensin converting enzyme 
(ACE) or is transformed by carboxypeptidase N to its des-Arg-metabolite, which can react with BKR1 and, 
to a much lesser extent, with BKR2, thereby also inducing vasodilation and edema formation. 
Modified from Busse P and Christiansen C;N Engl J Med 2020;382(12):1136-1148 and Cicardi M, Zuraw 
BL;J Allergy Clin Immunol Pract 2018;6:1132-1141. 
 
